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THE carcinogenic action of urethan (ethyl carbamate), once thought specific
for pulmonary tissue (see review by Shimkin, 1955), has recently been found to
extend to other tissues. Tannenbaum and Silverstone (1958) using repeated skin
applications of urethan in 3 strains of mice, were able to demonstrate induction
or enhancement of pulmonary adenomas, mammary carcinomas, malignant
mesenchymal tumours in the interseapular fat, eystoadenomas of the lacrimal
gland and blood cysts in the liver. The hemorrhagic cystic lesions in the liver
ofurethan-treated mice have been observedby severalinvestigators (Kirschbaum,
Bell and Gordon, 1949; Roe and Salaman, 1954; Berenblum and Haran, 1955;
Heston, Vlahakis and Deringer, 1960; Kawamoto et al., 1961) and differently
interpreted. Heston et al. (1960) observed an increase in the incidence of hepa-
tomas in urethan-treated C3H mice. Pietra and Shubik (1960) reported the
induction ofmelanotic tumours of the skin ofurethan-treated hamsters. For the
epidermis of the mouse, urethan has been show-n to have an initi'ating action
which can be completed by subsequent or alternate applications of croton oil
(Salaman and Roe, 1953 ; Graffi et al., 1953). In a preliminary report, Lindsay
and Bielschowsky (1956) recorded the induction of squamous cen tumours ofthe
skin in mice using topical applications of urethan alone. Urethan given orally
induced squamous cell papiRomas of the forestomach of the mouse and of the
hamster (Berenblum and Haran-Ghera, 1957 ; Pietra and Shubik, 1960). In the
studies of Kawamoto, Kirschbaum and Taylor (1958) and of Berenblum and
Trainin (1960), although urethan alone has not been found to exert aleukemogenic
action,- it has been reported to increase and accelerate the incidence of leukemias
induced by X-rays, estrogens or methylcholanthrene. In the most recent report
of Kawamoto et al. (1961) urethan, given alone, failed to augment the already
high incidence of leukemia in AKR and C58 mice and only slightly accelerated
its onset. From their study, Berenblum and Trainin (1960) suggested that
urethan acts as a promoting factor in leukemogenesis in C57BL/6 mice. How-
ever, Pietra, Rappaport and Shubik (1961) observed an early occurrence of
lymphomas in Swiss mice injected at birth with urethan.
The present investigation was stimulated by the observation of a few skin
papillomas in a group of male Swiss mice given urethan in the drinking water.
These papillomas arose on the skin of the lower back where ulcerations and
scarring from fighting had occurred. To confirm this finding, 2 groups of mice,
males and females, were given urethan in the clrinking water. The number of
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skin tumours occurring was again too small to be safely interpreted, but in the
same experiment a high incidence ofmalignant lymphomas was observed.
MATERIAL AND METHODS
Swiss albino mice, from the colony originally obtained from the Roscoe B.
Jackson Memorial Laboratory, Bar Harbor, Maine, and bred randomly in this
laboratory since 1951, were used. They were housed in plastic cages with wood
shavings in groups of 10 according to sex, fed Rockland diet in pellets and tap
water ad libitum with the exception to be described.
The experimental group originated from a number of litters born within a
few days. At 10 weeks of age, 100 females, weighing from 19 to 26 g. (average
24-8 g.) and 100 males weighing from 24 to 35 g. (average 28-6 g.) were selected
and given 0-4 per cent urethan (Fisher Scientific Co.) in the drinking water.
After 10 days, the average weight had decreased to 21-7 g. in the females and to
24-8 g. in the males; therefore the treatment was stopped and the animals were
given tap water until the original weight was restored. The interval lasted 10
days and was followed by a second, final period of 10 days of urethan treatment,
which again resulted in a weight loss and in addition 5 deaths among the males.
From the total water consumption during the 20 days of treatment, it was cal-
culated that each female received approximately 240 mg. and each male ap-
proximately 320 mg. of urethan.
As a control, 100 females and 100 males, selected in the same way as the
experimental animals, were kept untreated.
During the first 40 weeks from the beginning of the experiment, the animals
of the experimental group were allowed to die spontaneously or killed when
moribund. Then, at the 42nd week, that is at I year of age, most of the animals
had dvs-pnea and therefore it was decided to kill all the survivors. The control
groups were,kept until spontaneous death or killed when in poor condition.
Complete pathological study was done on all animals. In a few instances the
histological diagnosis was omitted or limited because ofdecomposition.
RESULTS
The number of survivors at various ages and the number ofmalignant lymph-
omas observed are show-n in Table 1.
TABLEI.-The Occurrence ofMalignant Lymphomas in Swim Mice
Treated with Urethan and Untreated
Number of mice with malignant
Groups Number of survivors (weeks ofage) lymphomas (weeks ofage)
15- 21- 26--- 31- 36- 41- 46- 51- Over Total
10 20 30 40 50 60 70 80 90 100 20 25 30 35 40 45 50 60 61 number
Urethan 0-4 100 98 87 62 30 - 0 2 4 13 5 1 1 2 28
percentin
drinking I00 89 84 56 27 - 0 0 1 3 5 0 1 5 15
water for
20 days
Control . y
. 100 100 100 89 82 70 57 41 18 . 0
Control S
. 100 98 89 81 57 45 25 13 . 0
0 0 0 3 1 1 5 6 . 16
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In the urethan-treated group, the first 2 lymphomas occurred in females
dying at 23 and 24 weeks of age, that is 8 and 9 weeks after the end of treatment.
Of 28 lymphomas observed in the females, 24 occurred before the 40th week of
age, that is before 25 weeks hadelapsed from the end oftreatment. The incidence
of lymphomas in the urethan-treated males was almost one-half of that in the
females ; 9 out of 15 occurred before the 40th week of age.
In the control group, 16 females developed malignant lymphomas; 10 died
before the 60th week of age, only 3 of them before the 40th week. Among the
males, fewer lymphomas were observed. Not a single male died of lymphoma
before the 40th week of age, 2 died with lymphomas before and 2 others after
the 60th week.
The great majority of the lymphomas occurring before the 50th week of age
were of lymphocytic type (lymphosarcomas) with diff-erent degrees of differentia-
tion. There were also several stem cell lymphomas distributed in both experi-
mental and control groups. Both these types of lymphomas were usually
generalized, but on many occasions their preponderant origin in the thymus was
still evident. The majority of the lymphomas observed in animals dying after
the 50th week were of the histiocytic type (reticulum cell sarcomas). Only I
urethan-treated female which died at the 66th week had granulocytic leukemia.
Eightv-six females and 78 males of the urethan-treated mice had multiple
lung adenomas ; considering that some animals died in the very beginning of the
experiment, the incidence of lung adenomas approaches 100 per cent in both
sexes. In the control group, 23 females and 9 males died with lung adenomas;
of these 3 of each sex died between the 40th and 60th week, the others after the
60th week. In the urethan-treated group, there were 2 females with mammary
tumours which were both recognized at 44 weeks of age. Among the controls,
13 females developed mammary tumours, 6 at I year of age, the others after
the 60th week. Multiple small hemangiomas of the liver were observed in several
urethan-treated animals of both sexes, which died or were killed after the 40th
week of age; the liver parenchyma was otherwise normal. One hemangioma of
the uterine wall and 3 hemangiomas of the spleen were also seen. Among the
treated animals, 3 males and 2 females had a total of 9 papillomas and I sebaceous
carcinoma of the skin; 2 females had multiple papillomas of the forestomach
I male had a renal tubular adenoma.
DISCUSSION
The short-term administration of a large amount of urethan to Swiss mice
resulted in an earlier development and higher incidence of malignant lymphomas
when compared with untreated Swiss mice of corresponding sex. Females
developed twice as many lymphomas as the males. Most of the lymphomas
observed before the 50th week were of the lymphocytic type (lymphosarcomas)
while beyond that age histiocytic (reticulum cell) sarcomas predominated. Con-
sidering that the majority of the lymphomas in the controls occurred after the
50th week, this histological observation seems to corroborate the numerical
difference between the experimental and control groups, even though the bio-
logical significance of the various types of lymphomas is unknown. However,
the sex ratio of the induced lymphomas which followed the ratio observed in the
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and accelerated a process which may have developed without any specific treat-
ment. This situation could be equated with the variation in response to urethan
observed in strains which, untreated, have in the same order a different incidence
of mammary tumours (Tannenbaum and Silverstone, 1958). There are many
similar examples in careinogenesis and it becomes almost a matter of semantics
to decide if each carcinogenic process should be labeRed as induction or enhance-
ment.
it is interesting to note that the occurrence of malignant lymphomas or
leukaemias with urethan alone has not been reported in the studies of Kawamoto
et al. (1958) and ofBerenblum and Trainin (1960) nor in thelong-termexperiments
of Tannenbaum and Silverstone (1958). In those studies several strains of mice
have been used, the lymphoma incidence of which does not appear to be much
different from that observed in our untreated Swiss mice. The different result
might be explained by the different dosage and way ofadministration of urethan.
The present experiment differs from the others in the larger amount of urethan
given continuously for two periods of 10 days each, reaching a transient toxic
effect.
The experiments of Berenblum and Trainin (1960) are demonstrative of a
promoting action of urethan on leukemogenesis. Although the two periods of
treatment of our experiment might be suggestive of some sort of two stage action,
it is clear that we do not have data to substantiate this suggestion. For the
present, it is only possible to consider that the leukemogenic effect has been
achieved by a large amount of urethan given in a short period, which should
indicate a direct action ofurethan on the lymphatic tissue.
SUMMARY
The administration to Swiss mice of 0-4 per cent urethan in the drinking water
for two periods of 10 days with an interval of I0 days, resulted in a transient
toxic effect and in the rapid occurrence ofmalignant lymphomas. Twenty-eight
per cent of the females and 15 per cent of the males developed lymphomas,
whereas among the controls the incidence was 16 per cent in the females and
4 per cent in the males. In the urethan-treated animals, the majority oflymph-
omas occurred before the .50th week ofage and most ofthem were oflymphocytic
type, while in the controls most lymphomas occurred after the 50th week and
were ofhistiocytic type.
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